{
    "root": "2fbd11a9-ac12-10a0-e063-6394a90a99b6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "OSELTAMIVIR PHOSPHATE",
    "value": "20250307",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "OSELTAMIVIR PHOSPHATE",
            "code": "4A3O49NGEZ"
        }
    ],
    "indications": "oseltamivir phosphate influenza neuraminidase inhibitor ( nai ) indicated : treatment acute , uncomplicated influenza b patients 2 weeks age older symptomatic 48 hours . ( 1.1 ) prophylaxis influenza b patients 1 year older . ( 1.2 ) limitations : substitute annual influenza vaccination . ( 1.3 ) consider available information influenza susceptibility patterns treatment effects deciding whether . ( 1.3 ) recommended patients end-stage renal disease undergoing dialysis . ( 1.3 )",
    "contraindications": "treatment influenza adults adolescents ( 13 years older ) : 75 mg twice daily 5 days ( 2.2 ) pediatric patients 1 12 years age : based weight twice daily 5 days ( 2.2 ) pediatric patients 2 weeks less 1 year age : 3 mg/kg twice daily 5 days ( 2.2 ) renally impaired adult patients ( creatinine clearance > 30-60 ml/min ) : reduce 30 mg twice daily 5 days ( 2.4 ) renally impaired adult patients ( creatinine clearance > 10-30 ml/min ) : reduce 30 mg daily 5 days ( 2.4 ) esrd patients hemodialysis : reduce 30 mg immediately 30 mg every hemodialysis cycle . treatment duration exceed 5 days ( 2.4 ) esrd patients capd : reduce single 30 mg dose immediately ( 2.4 ) prophylaxis influenza adults adolescents ( 13 years older ) : 75 mg daily least 10 days ( 2.3 ) community outbreak : 75 mg daily 6 weeks ( 2.3 ) pediatric patients 1 12 years age : based weight daily 10 days ( 2.3 ) community outbreak : based weight daily 6 weeks ( 2.3 ) renally impaired adult patients ( creatinine clearance > 30-60 ml/min ) : reduce 30 mg daily ( 2.4 ) renally impaired adult patients ( creatinine clearance > 10-30 ml/min ) : reduce 30 mg every day ( 2.4 ) esrd patients hemodialysis : reduce 30 mg immediately 30 mg alternate hemodialysis cycles recommended duration prophylaxis ( 2.4 ) esrd patients capd : reduce 30 mg immediately 30 mg weekly recommended duration prophylaxis ( 2.4 )",
    "warningsAndPrecautions": "oseltamivir phosphate capsules , usp 30-mg capsules ( 30 mg free base equivalent phosphate salt ) : hard gelatin , white opaque/white opaque capsule , imprinted black ink `` n `` body black ink `` 1008 `` cap . available blister packages 10 ( ndc 70710-1008-2 ) . 45-mg capsules ( 45 mg free base equivalent phosphate salt ) : hard gelatin , light blue grey opaque/ light blue grey opaque capsule , imprinted black ink `` n `` body black ink `` 1009 `` cap . available blister packages 10 ( ndc 70710-1009-2 ) . 75-mg capsules ( 75 mg free base equivalent phosphate salt ) : hard gelatin , white opaque/ light blue grey opaque capsule , imprinted black ink `` n `` body black ink `` 1010 `` cap . available blister packages 10 ( ndc 70710-1010-2 ) . storage store capsules 25°c ( 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "patients known serious hypersensitivity oseltamivir components oseltamivir phosphate capsules ( 4 )",
    "indications_original": "Oseltamivir Phosphate is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 )",
    "contraindications_original": "Treatment of influenza Adults and adolescents (13 years and older): 75 mg twice daily for 5 days ( 2.2 ) Pediatric patients 1 to 12 years of age: Based on weight twice daily for 5 days ( 2.2 ) Pediatric patients 2 weeks to less than 1 year of age: 3 mg/kg twice daily for 5 days ( 2.2 ) Renally impaired adult patients (creatinine clearance >30-60 mL/min): Reduce to 30 mg twice daily for 5 days ( 2.4 ) Renally impaired adult patients (creatinine clearance >10-30 mL/min): Reduce to 30 mg once daily for 5 days ( 2.4 ) ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after every hemodialysis cycle. Treatment duration not to exceed 5 days ( 2.4 ) ESRD patients on CAPD: Reduce to a single 30 mg dose immediately ( 2.4 ) Prophylaxis of influenza Adults and adolescents (13 years and older): 75 mg once daily for at least 10 days ( 2.3 ) Community outbreak: 75 mg once daily for up to 6 weeks ( 2.3 ) Pediatric patients 1 to 12 years of age: Based on weight once daily for 10 days ( 2.3 ) Community outbreak: Based on weight once daily for up to 6 weeks ( 2.3 ) Renally impaired adult patients (creatinine clearance >30-60 mL/min): Reduce to 30 mg once daily ( 2.4 ) Renally impaired adult patients (creatinine clearance >10-30 mL/min): Reduce to 30 mg once every other day ( 2.4 ) ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after alternate hemodialysis cycles for the recommended duration of prophylaxis ( 2.4 ) ESRD patients on CAPD: Reduce to 30 mg immediately and then 30 mg once weekly for the recommended duration of prophylaxis ( 2.4 )",
    "warningsAndPrecautions_original": "Oseltamivir Phosphate Capsules, USP\n                  \n                  30-mg capsules (30 mg free base equivalent of the phosphate salt): Hard Gelatin, White Opaque/White Opaque Capsule, imprinted with black ink \"N\" on the body and black ink \"1008\" on the cap. Available in blister packages of 10 (NDC 70710-1008-2).\n                  45-mg capsules (45 mg free base equivalent of the phosphate salt): Hard Gelatin, Light Blue Grey Opaque/ Light Blue Grey Opaque Capsule, imprinted with black ink \"N\" on the body and black ink \"1009\" on the cap.\n \n   Available in blister packages of 10 (NDC 70710-1009-2).\n\n \n                  75-mg capsules (75 mg free base equivalent of the phosphate salt): Hard Gelatin, White Opaque/ Light Blue Grey Opaque Capsule, imprinted with black ink \"N\" on the body and black ink \"1010\" on the cap.\n \n    Available in blister packages of 10 (NDC 70710-1010-2).\n\n \n                  \n                     Storage\n                  \n                  Store the capsules at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Patients with known serious hypersensitivity to oseltamivir or any of the components of oseltamivir phosphate capsules ( 4 )"
}